scholarly journals Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study

2019 ◽  
Vol Volume 12 ◽  
pp. 8263-8273 ◽  
Author(s):  
Moonkyoo Kong ◽  
Ji-Youn Sung ◽  
Seung Hyeun Lee
Keyword(s):  
Lung Cancer ◽  
Reactive Oxygen Species ◽  
Pilot Study ◽  
Small Cell Lung Cancer ◽  
Prognostic Marker ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iii ◽  
Oxygen Species ◽  
Small Cell Lung

Curcumin exerts cytotoxicity dependent on reactive oxygen species accumulation in non-small-cell lung cancer cells

2019 ◽  
Vol 15 (11) ◽  
pp. 1243-1253 ◽  
Author(s):  
Cuijuan Wang ◽  
Xingguo Song ◽  
Ming Shang ◽  
Wei Zou ◽  
Mengping Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Reactive Oxygen Species ◽  
Small Cell Lung Cancer ◽  
Cancer Cells ◽  
Cell Lung Cancer ◽  
Reactive Oxygen ◽  
Small Cell ◽  
Lung Cancer Cells ◽  
Oxygen Species ◽  
Small Cell Lung

Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells

2007 ◽  
Vol 292 (6) ◽  
pp. L1488-L1494 ◽  
Author(s):  
Ramasamy Jagadeeswaran ◽  
Sujatha Jagadeeswaran ◽  
Vytas P. Bindokas ◽  
Ravi Salgia
Keyword(s):  
Lung Cancer ◽  
Reactive Oxygen Species ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Receptor Tyrosine Kinase ◽  
Small Cell ◽  
Oxygen Species ◽  
Small Cell Lung ◽  
Met Receptor Tyrosine Kinase

Small cell lung cancer (SCLC) is a difficult disease to treat and sometimes has overexpression or mutation of c-Met receptor tyrosine kinase. The effects of c-Met/hepatocyte growth factor (c-Met/HGF, ligand for c-Met) on activation of reactive oxygen species (ROS) was determined. HGF stimulation of c-Met-overexpressing H69 SCLC cells (40 ng/ml, 15 min) resulted in an increase of ROS, measured with fluorescent probe 2′-7′-dichlorofluorescein diacetate (DCFH-DA) or dihydroethidine (DHE) but not in c-Met-null H446 cells. ROS was increased in juxtamembrane (JM)-mutated variants (R988C and T1010I) of c-Met compared with wild-type c-Met-expressing cells. ROS was significantly inhibited by preincubation of SCLC cells with pyrrolidine dithiocarbamate (PDTC, 100 μM) and/or SU11274 (small molecule c-Met tyrosine kinase inhibitor, 2 μM) for 3 h. PDTC and SU11274 also abrogated the HGF proliferative signal and cell motility in a cooperative fashion. H2O2 treatment of SCLC cells (over 15 min) led to phosphorylation of c-Met receptor tyrosine kinase and further upregulated downstream phosphorylation of phospho-AKT, ERK1/2, and paxillin in a dose-dependent manner (125 μM to 500 μM). c-Met is an important target in lung cancer, and the pathways responsible for ROS generation together may provide novel therapeutic intervention.

scholarly journals Reactive oxygen species modulator 1 expression predicts lymph node metastasis and survival in early-stage non-small cell lung cancer

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0239670
Author(s):  
Taehee Kim ◽  
Yoon Jin Cha ◽  
Ji Hyun Park ◽  
Arum Kim ◽  
Yong Jun Choi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Reactive Oxygen Species ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Oxygen Species ◽  
Small Cell Lung ◽  
Node Metastasis

Reactive oxygen species modulator 1 (romo1) causes cell hyperplasia and promotes cancer cell invasion. Based recent studies, the overexpression of romo1 is associated with lymphatic metastasis and poor prognosis in lung cancer. We aimed to evaluate associations between romo1 expression and lymph node metastasis in non-small cell lung cancer (NSCLC). Clinical data and pathological results were retrospectively reviewed for 98 subjects diagnosed with NSCLC and who underwent surgical biopsy between 1994 and 2009. A total 98 tumor specimens were analyzed. The romo1 H score was correlated with stage and was significantly higher in subjects with lymph node metastasis than in those without metastasis (173 vs 116; P < 0.05). The area (%) of grade 1 expression was significantly smaller (19.5 vs 37.0; P = 0.005) and the area of grade 3 expression was significantly larger (27.9 vs 6.00; P < 0.001) in subjects with lymph node metastasis than in those without metastasis. In stage I patients, disease free survival (DFS) (191 ± 18.8 vs. 75.6 ± 22.4 months, P = 0.004) was significantly longer in the low romo1 group than in the high romo1 group. A multivariate analysis showed a significant association between high romo1 expression and poor DFS (hazard ratio 5.59, 95 confidence interval, 1.54–20.3, P = 0.009). These findings support the prognostic value of romo1 in NSCLC, especially in stage I.

Sign in / Sign up

Export Citation Format

Share Document